 |
 |

Structural Brain Differences Between Never-Treated Patients With Schizophrenia, With and Without Dyskinesia, and Normal Control Subjects
A Magnetic Resonance Imaging Study
Robin G. McCreadie, DSc, MD, FRCPsych;
Rangaswamy Thara, MD, PhD;
Ramachandran Padmavati, MD;
Tirupati N. Srinivasan, MD;
Sandeep D. Jaipurkar, MD
Arch Gen Psychiatry. 2002;59:332-336.
ABSTRACT
Background In south India, abnormal movements indistinguishable from tardive dyskinesia
have been observed in chronically ill patients with schizophrenia who have
never received antipsychotic medication. The present study, using magnetic
resonance imaging, examines brain structure in such patients, in those without
dyskinesia, and in normal control subjects.
Methods Chronically ill patients with schizophrenia with and without dyskinesia
and controls were identified in villages south of Chennai, India (each group,
n = 31). Patients' mental state was assessed by the Positive and Negative
Syndrome Scale for schizophrenia, dyskinesia by the Abnormal Involuntary Movements
Scale, and parkinsonism by the Simpson and Angus scale. In patients and controls,
magnetic resonance imaging measured the volume of the caudate and lentiform
nuclei and the lateral ventricle-hemisphere ratio.
Results The left lentiform nucleus was significantly (11%) larger in patients
with dyskinesia compared with controls, and the right lateral ventricle-hemisphere
ratio was significantly (33%) larger in patients without dyskinesia compared
with controls. In all 3 groups, there were significant positive correlations
between age and ventricle-hemisphere ratio. In controls, but not in patients,
there were significant negative correlations between age and the volume of
the caudate and lentiform nuclei.
Conclusions Never-treated patients with dyskinesia may have striatal pathologic
conditions and may represent a subgroup of patients with schizophrenia; in
those without abnormal movements, cortical atrophy is more apparent. The schizophrenic
process may interfere with normal age-related anatomical changes in the basal
ganglia.
INTRODUCTION
IN SOUTH INDIA, abnormal movements indistinguishable from tardive dyskinesia
(TD) are not uncommon in chronically ill patients with schizophrenia who have
never received antipsychotic medication.1-2
We sought to determine whether there are any differences in brain structure
between 2 patient groups with and without dyskinesia, and how the 2 groups
compare with normal subjects. For the past 20 years, using computed tomography
or magnetic resonance imaging (MRI), researchers on TD have measured cerebral
atrophy and the size of the basal ganglia in treated patients, with inconsistent
results.3-14
For example, studies have shown no differences between patients with and without
TD in the size of the caudate3-4,7, 10, 12
or lentiform nucleus9-10,12-13;
other studies in patients with TD have found a larger caudate nucleus14; and others have found a smaller caudate5, 9, 13 or lentiform nucleus.5 In 5 reports15-19
of drug-naive first-episode patients, 3 found a reduction in volume of the
caudate nucleus in patients compared with control subjects16-17,19;
the other 2 found no differences.15, 18
In 2 of the studies, there were no differences in the size of the lentiform
nucleus.17-18
In the present MRI study, we report on the volume of the caudate and
lentiform nuclei and the lateral ventricle-hemisphere ratio in never-treated
chronically ill patients with and without dyskinesia, and in normal control
subjects.
SUBJECTS AND METHODS
SUBJECTS
Patients were identified predominantly in and around the village of
Thiroporur, 40 km south of Madras (Chennai), in south India. Here there is
an outreach center run by SCARF (Schizophrenia Research Foundation, Chennai,
India), a nongovernmental organization specializing in research and community
care of patients with schizophrenia. Community mental health workers, trained
to recognize major mental illness, bring to the center individuals from villages
within a 20-km radius for assessment and treatment.
Patients were recruited if they fulfilled DSM-IV20 criteria for schizophrenia and had never received
antipsychotic medication. The diagnosis was made through mental state examination
results (see "Assessment") and a history obtained from patients and relatives.
The diagnosis was made by 1 of 2 psychiatrists (R.T. or R.P.), each of whom
has postgraduate qualifications in psychiatry and has been practicing clinicians
for more than 15 years. Patients were excluded if there was a history of seizures.
No patients were abusing street drugs. Two male patients used alcohol once
or twice monthly. No patient had ever received psychotropic medication. Analgesics
and antipyretics were taken as needed for short periods.
The study was approved by the ethical review board at SCARF. Written
consent was inappropriate as almost all subjects were illiterate. All patients
gave informed oral consent, witnessed by their next of kin, who also gave
informed oral assent, and a SCARF staff member. The oral consent was recorded
in the patient's case record. Because almost all patients and their family
members had to travel a long distance from their homes to the city for MRI,
a detailed oral explanation of the study and the procedures involved was provided
to them before obtaining their consent.
ASSESSMENT
Mental state was assessed by the Positive and Negative Syndrome Scale
(PANSS) for schizophrenia.21 The ratings were
made by 2 psychiatrists (R.T. and R.P.) fluent in English and Tamil (the local
language) and trained in the use of the PANSS. The interrater reliability
of the 2 psychiatrists in a previous unpublished study was high ( =
0.86). One psychiatrist (R.G.M.) examined each patient for evidence of dyskinesia,
using the Abnormal Involuntary Movements Scale,22
and of parkinsonism, using the Simpson and Angus scale.23
A patient was said to have probable dyskinesia if he or she fulfilled Schooler
and Kane criteria,24 namely, movements were
"mild" in at least 2 of 7 individual areas rated or "moderate" in at least
1 area.
For each patient thus identified, another patient who did not have dyskinesia
was recruited and matched for sex, age (within 5 years), and age at onset
of illness (also within 5 years). Also recruited for each patient with dyskinesia
was a normal control subject in the same village, matched for sex and age
(within 5 years). In addition to the controls themselves, at least 1 other
member of their families was interviewed to exclude a history of psychiatric
disorder in the controls, using DSM-IV criteria.
All subjects were villagers of low socioeconomic class.
MRI SCANNING
Magnetic resonance imaging scans were carried out using a scanner with
uniform protocol and software (MR Vectra II, version 4.10, O.5T; GE Medical
Systems, Milwaukee, Wis). One neuroradiologist (S.D.J.), blinded to subject
and dyskinesia status, made all the measurements. The subject's head was positioned
in a head coil fixation device, centered at the orbitomeatal line with no
angulation. A spin echo sequence was used to obtain T2-weighted images in
the axial plane.
For a volumetric study of the basal ganglia, lateral ventricles, and
cerebral hemispheres at the level of the caudate nucleus, a fast inversion
recovery sequence was used. Transaxial images were obtained using the following
sequence: repetition time, 5000 milliseconds; echo time, 13 milliseconds;
inversion time, 600 milliseconds; number of excitations, 2; matrix size, 192
x 256; slice thickness, 3 mm; number of contiguous slices with no gap,
24; field of view, 30 cm; and imaging options, rectangular-pixel, no phase
wrap saturationhead first. All the axial images were aligned along
the canthomeatal orientation.
The head of the caudate nucleus was defined in the transaxial plane
as the mass of grey matter bounded inferolaterally by the anterior limb of
the internal capsule, superolaterally by the external capsule, and medially
by the lateral walls of the lateral ventricles. The superior extent of the
caudate nucleus was defined up to the confluence of anterior and posterior
horns of the lateral ventricles.
The lentiform nucleus was defined as the grey matter bounded by the
internal and external capsules. Region tracing for the superior extent of
the lentiform nucleus (putamen) was done until the thalamus disappeared and
the body and the tail of the caudate nucleus became continuous. The third
ventricle was used to identify the inferior extent of the lentiform nucleus.
All measurements were in cubic centimeters. The caudate nucleus and
the lentiform nucleus were separately defined on the left and right side for
each subject for volumetric measurements.
An image was displayed on the screen from the set of inversion recovery
sequences. The area of interest (ie, caudate nucleus or lentiform nucleus)
was defined by 2 sets of fixed intensities within a cursor-defined region.
A minimal pixel intensity of 50 and a maximum pixel intensity of 150 were
given. The cursor was positioned over the area of interest (caudate or lentiform
nucleus) and its size adjusted. Trace function was used to draw the area of
interest. The area in square centimeters was posted on the screen. A manual
mode was used to collect data from each image within the selected range for
the accurate definition of the area of interest. This was repeated separately
for the caudate nucleus and lentiform nucleus on either side. The volume was
calculated by the MRI software by summing the areas.
Cerebral hemisphere volume and the lateral ventricular volumes were
measured in 2 contiguous sections. The inferior section was selected where
both Monro foramina were seen. The sulcal spaces were excluded for volume
measurements.
Not all scan measurements were available on all patients and control
subjects (see the "Results" section).
STATISTICAL ANALYSIS
As a result of the methods used, we recruited 3 sets of matched pairs:
patients with and without dyskinesia, patients with dyskinesia and controls,
and patients without dyskinesia and controls. Between-group differences in
the size of brain structures were measured by paired t
tests. We compared not only differences in absolute size of the caudate and
lentiform nuclei but also the caudate-hemisphere volume and lentiform-hemisphere
volume ratios.
Within-group correlations between age and the size of different brain
structures were measured by Pearson product moment correlation coefficient.
As there were many correlations, we used the Scheffé multiple comparison
test to assess the level of significance. A 5% level of significance was used.
All tests were 2-tailed.
RESULTS
Thirty-one patients with dyskinesia (18 men and 13 women) were identified,
with the same number and sex distribution of patients without dyskinesia and
of controls. There were no significant differences between patients with and
without dyskinesia in age, age at onset of illness, and severity of mental
state, as assessed by the PANSS total score and subscales, nor between patients
with dyskinesia and controls in age (Table
1). Patients with dyskinesia had higher scores on the Simpson and
Angus parkinsonism scale than did patients without dyskinesia.
|
|
|
|
Table 1. Demographic and Clinical Data*
|
|
|
Three patients with dyskinesia and 1 patient without dyskinesia refused
to be scanned. Through a miscommunication between the clinicians and the radiologist,
the latter failed to measure ventricle and hemisphere volumes in the first
16 patients, 5 with dyskinesia and 11 without dyskinesia. Therefore, the number
of matched pairs was substantially less in the comparisons of ventricle and
hemisphere volumes and basal ganglia-hemisphere ratios.
There were 2 statistically significant between-group differences in
brain structure (Table 2). First,
the absolute size of the lentiform nucleus was largest in patients with dyskinesia,
followed by patients without dyskinesia, and then controls. The difference
between patients with dyskinesia and controls was statistically significant
for the left lentiform nucleus, with the former 11% larger than the latter.
Second, the lateral ventricle-hemisphere ratio was largest in patients without
dyskinesia, followed by patients with dyskinesia, and then controls. The difference
between patients without dyskinesia and controls was statistically significant
on the right side, with the former 33% larger than the latter.
|
|
|
|
Table 2. Magnetic Resonance Imaging Measurements*
|
|
|
We then considered hemisphere size in comparing the size of the left
lentiform nucleus in the patients with dyskinesia and controls by using the
lentiform-hemisphere ratio. There were only 23 matched pairs in whom both
the lentiform nucleus and hemisphere measurements were available. In this
smaller group, the mean absolute value of the lentiform nucleus was not significantly
higher in the patients with dyskinesia (mean [SD], 3.37 [0.60] vs 3.10 [0.79]
mL), nor was the lentiform-hemisphere ratio greater.
In the dyskinesia group, the scores on the PANSS subscales and parkinsonism
scale did not correlate significantly with the size of the left lentiform
nucleus. In the group without dyskinesia, the scores on the PANSS subscales
and parkinsonism scale did not correlate significantly with the lateral ventricle-hemisphere
ratio.
When within-group correlations were calculated between age, the size
of the caudate and lentiform nuclei, and the ventricle-hemisphere ratio, in
all 3 groups there were significant positive correlations between age and
ventricle-hemisphere ratio (Pearson r range, 0.44-0.73).
In the controls, but not in the patients, there were significant negative
correlations between age and the size of the caudate and lentiform nuclei
(r range, -0.48 to -0.49). In the patients,
there were no significant correlations between duration of illness and size
of the caudate and lentiform nuclei, or between duration of illness and ventricle-hemisphere
ratio.
COMMENT
We recruited to our study chronically ill, never-treated patients with
schizophrenia. They were, on average, middle-aged and had been ill for about
10 years. The late age at onset of illness reflects the difficulty with our
rural Indian patients in retrospectively assessing the exact age at onset.
We considered this to be the first appearance of positive schizophrenic symptoms,
as estimated by the patient or family, and obviously not first contact with
psychiatric services or hospital admission. The apparent late onset of illness
raises the possibility that some of our patients had an organic psychotic
illness. However, we excluded from the study patients who had a history of
seizures or alcohol or other drug abuse.
We are confident that the patients, although ill for many years, had
not been exposed to antipsychotic medication. The SCARF team has been working
in the Thiropuror area for more than 6 years, and the health workers drawn
from the villages know the families well, especially details about health
conditions and treatment. Also, there are no mental health services in this
region except for the outreach program of SCARF. Antipsychotics are not available
in any of the local stores; therefore, it is improbable that any of these
patients would have received any antipsychotic medication.
We are also satisfied that the abnormal movements rated were indistinguishable
from TD. The rater (R.G.M.) has had extensive experience in the use of the
Abnormal Involuntary Movements Scale2 in TD
and has made more than 1500 ratings using this scale.
There are, however, limitations to our study. Patients who were eventually
recruited to the study had first to agree to come with outreach workers to
the SCARF center for assessment. They had to agree to be examined by clinicians
and then travel with their relatives to the city (up to 100 km) for an MRI
scan. All this demanded a high degree of cooperation from the patients and
their families. We cannot be certain, therefore, that those patients are representative
of the large numbers of never-treated patients in and around Thiropuror.
Another limitation is that the diagnosis of schizophrenia was made on
clinical grounds, albeit by experienced clinicians, using the PANSS assessment
and history from the patients and their families. A structured diagnostic
interview was not carried out.
There were several radiological limitations. First, the imager had a
low field-strength. Second, through a miscommunication, ventricle and hemisphere
volumes were not measured in the first 16 patients. Third, one radiologist
alone was responsible for all MRI measurements. Fourth, there was only partial
coverage of the brain for the hemisphere values.
Compared with normal subjects, never-treated patients with dyskinesia
had a larger lentiform nucleus, especially on the left side, and never-treated
patients without dyskinesia had a larger lateral ventricle-hemisphere ratio,
especially on the right side. This suggests that the patients with dyskinesia
may have striatal pathologic conditions and may represent a subgroup of schizophrenia.
In those without abnormal movements, cortical atrophy was more apparent. However,
these results should be interpreted with caution. When we attempted to consider
the effect of hemisphere volume, the number of matched pairs fell to 23. In
this smaller group, although the difference in mean absolute lentiform nucleus
volume between the patients with dyskinesia and the controls was the same
as in the total group, the difference was no longer statistically significant,
nor was the difference in mean lentiform-hemisphere ratio. Another note of
caution is that the significant differences were between patients and controls;
there were no statistically significant differences between patients with
and without dyskinesia.
Our findings suggest that the structure in the basal ganglia of patients
with dyskinesia that differs from that of controls is the lentiform nucleus,
not the caudate nucleus. As stated in the introduction, most studies of TD
in treated patients and of spontaneous dyskinesia in first-episode patients
have found differences in the caudate nucleus rather than the lentiform nucleus.
However, differences in the lentiform nucleus have also been seen in studies
in which patients not classified by TD status have been compared with normal
controls.25-26 For example, one
study25 found an increased lentiform nucleus
in patients with chronic schizophrenia compared with controls; as in our study,
the increase was greater on the left side. This study also found that the
earlier the age of onset of illness, the greater was the increase in lentiform
nucleus volume. The authors speculated that an increased lentiform nucleus
volume in patients with schizophrenia could be related to the failure of late
processes of maturation that normally would result in its volume reduction.
Longitudinal studies of drug-naive, then treated patients, or comparisons
of drug-naive and treated patients, suggest that antipsychotic medication
may enlarge the basal ganglia.15-16,27-28
Our study suggests that chronically ill patients who have never received medication
may also have an enlarged lentiform nucleus.
In the controls, there was an association between age and the size of
the basal ganglia and the ventricle-hemisphere ratio: the older the person,
the smaller the basal ganglia and the larger the ventricle-hemisphere ratio.
These age-related changes have been described previously in controls.29-30 In the patients, the relationship
between age and the ventricle-hemisphere ratio held; this also has been demonstrated
previously.31 However, there was no relationship
between age and the size of the basal ganglia. This suggests that the schizophrenic
process interferes with normal age-related anatomical changes in the basal
ganglia. One possible explanation is that age and illness duration have opposing
effects on basal ganglia volumes (ie, increased lentiform nucleus volume with
longer duration of illness). However, we found no correlation between duration
of illness and size of the basal ganglia.
We are further examining the differences between the never-treated patients
with and without movement disorders. It has recently been shown that there
may be a dopamine D3 receptor gene variation in patients with schizophrenia
with TD.32 This does not seem to be the case
in our patients with spontaneous dyskinesia.33
AUTHOR INFORMATION
Submitted for publication November 29, 2000; final revision received
May 30, 2001; accepted for publication August 13, 2001.
We thank the patients, relatives, and control subjects for their cooperation;
J. R. Ayankaran, MA, coordinator of the rural service at Thiropuror, India,
and the team of health care workers; Heather Barrington, MSc, for statistical
advice; and Susan Farrington, BA, for secretarial assistance.
Corresponding author and reprints: Robin G. McCreadie, DSc, MD, FRCPsych,
Department of Clinical Research, Crichton Royal Hospital, Dumfries DG1 4TG,
Scotland (e-mail: rgmccreadie_crh{at}compuserve.com).
From the Department of Clinical Research, Crichton Royal Hospital,
Dumfries, Scotland (Dr McCreadie); and the Schizophrenia Research Foundation
(Drs Thara, Padmavati, and Srinivasan) and Department of Neuroradiology, Vijaya
Medical Centre (Dr Jaipurkar), Chennai, India.
REFERENCES
1. McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon MS. Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry. 1996;168:221-226.
FREE FULL TEXT
2. McCreadie RG, Latha S, Thara R, Padmavathi R, Ayankaran JR. Poor memory, negative symptoms and abnormal movements in never-treated
Indian patients with schizophrenia. Br J Psychiatry. 1997;171:360-363.
FREE FULL TEXT
3. Gelenberg AJ. Computerized tomography in patients with tardive dyskinesia. Am J Psychiatry. 1976;133:578-579.
WEB OF SCIENCE
| PUBMED
4. Jeste DV, Wagner RL, Weinberger DR, Rieth KG, Wyatt RJ. Evaluation of CT scans in tardive dyskinesia. Am J Psychiatry. 1980;137:247-248.
WEB OF SCIENCE
| PUBMED
5. Bartels M, Themelis J. Computerized tomography in tardive dyskinesia: evidence of structural
abnormalities in the basal ganglia system. Arch Psychiatr Nervenkr. 1983;233:371-379.
FULL TEXT
| PUBMED
6. Brainin M, Reisner T, Zeitlhofer J. Tardive dyskinesia: clinical correlation with computed tomography in
patients aged less than 60 years. J Neurol Neurosurg Psychiatry. 1983;46:1037-1040.
FREE FULL TEXT
7. Swayze 2nd VW, Yates WR, Andreasen NC, Alliger RJ. CT abnormalities in tardive dyskinesia. Psychiatry Res. 1988;26:51-58.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
8. Hoffman WF, Casey DE. Computed tomographic evaluation of patients with tardive dyskinesia. Schizophr Res. 1991;5:1-12.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
9. Mion CC, Andreasen NC, Arndt S, Swayze 2nd VW, Cohen GA. MRI abnormalities in tardive dyskinesia. Psychiatry Res. 1991;40:157-166.
FULL TEXT
| PUBMED
10. Harvey I, Ron MA, Murray R, Lewis S, Barker G, McManus D. MRI in schizophrenia: basal ganglia and white matter T1 times. Psychol Med. 1991;21:587-598.
WEB OF SCIENCE
| PUBMED
11. Ueyama K, Fukuzako H, Takeuchi K, Hirakawa K, Fukuzako T, Hokazono Y, Takigawa M, Matsumoto K. Brain atrophy and intellectual impairment in tardive dyskinesia. Jpn J Psychiatry Neurol. 1993;47:99-104.
PUBMED
12. Elkashef AM, Buchanan RW, Gellad F, Munson RC. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an
MRI quantitative study. Am J Psychiatry. 1994;151:752-755.
WEB OF SCIENCE
| PUBMED
13. Dalgalarrendo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia: possible relationship
with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci. 1994;244:272-277.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
14. Brown KW, White T, Wardlaw JM, Walker N, Foley D. Caudate nucleus morphology in tardive dyskinesia. Br J Psychiatry. 1996;169:631-636.
FREE FULL TEXT
15. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lermer G, Bogerts B, Wu H, Kinon B, Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients
taking antipsychotic drugs. Am J Psychiatry. 1994;151:1430-1436.
WEB OF SCIENCE
| PUBMED
16. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar M, Harvey P, Newman A, Schnur DB, Spiegel-Cohen J, Wei T, Machac J, Knesaurek K, Vallabhajosula S, Biren MA, Ciaravolo TM, Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated
and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry. 1998;55:235-243.
FREE FULL TEXT
17. Keshavan MS, Rosenberg D, Sweeney JA, Pettegrew JW. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry. 1998;155:774-778.
WEB OF SCIENCE
| PUBMED
18. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with
schizophrenia. Am J Psychiatr. 1998;155:1711-1717.
WEB OF SCIENCE
| PUBMED
19. Corson PW, Nopoulos P, Andreasen NC, Heckel D, Arndt S. Caudate size in first-episode neuroleptic-naive schizophrenic patients
measured using an artificial neural network. Biol Psychiatry. 1999;46:712-720.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition. Washington, DC: American Psychiatric Association; 1994.
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
22. Abnormal Involuntary Movements Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Pharmacology.
Rockville, Md: US Dept of Health, Education, and Welfare; 1976:534-537.
23. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
PUBMED
24. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
25. Jernigan TL, Zisook S, Heaton RK, Moranville JT, Hesselink JR, Braff DL. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral
cortex in schizophrenia. Arch Gen Psychiatry. 1991;48:881-890.
FREE FULL TEXT
26. Swayze V, Andreasen N, Alliger R, Yuh W, Ehrhardt J. Subcortical and temporal structures in affective disorder and schizophrenia:
a magnetic resonance imaging study. Biol Psychiatry. 1992;31:221-240.
WEB OF SCIENCE
| PUBMED
27. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment [letter]. Lancet. 1994;344:1434.
WEB OF SCIENCE
| PUBMED
28. DeLisi LE, Tew W, Xie S, Hoff AL, Sakuma M, Kushner M, Lee G, Shedlack K, Smith AM, Grimson R. A prospective follow-up study of brain morphology and cognition in
first-episode schizophrenic patients: preliminary findings. Biol Psychiatry. 1995;38:349-360.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
29. Jernigan TL, Press GA, Hesselink JR. Methods for measuring brain morphologic features on magnetic resonance
images: validation and normal aging. Arch Neurol. 1990;47:27-32.
FREE FULL TEXT
30. Jernigan TL, Archibald SL, Berhow MJ, Sowell ER, Foster DS, Hesselink JR. Cerebral structure on MRI, I: localization of age-related changes. Biol Psychiatry. 1991;29:55-67.
WEB OF SCIENCE
| PUBMED
31. Andreasen NC, Swayze 2nd VW, Flaum M, Yates WR, Arndt S, McChesney C. Ventricular enlargement in schizophrenia evaluated with computed tomographic
scanning: effects of gender, age, and stage of illness. Arch Gen Psychiatry. 1990;47:1008-1015.
FREE FULL TEXT
32. Steen VM, Løvlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia
in schizophrenic patients. Mol Psychiatry. 1997;2:139-145.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
33. Løvlie R, Thara R, Padmavathi R, Steen VM, McCreadie RG. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia
in never-medicated schizophrenic patients. Mol Psychiatry. 2001;6:6-7.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Spectrum of tardive syndromes: clinical recognition and management
Bhidayasiri and Boonyawairoj
Postgrad. Med. J. 2011;87:132-141.
ABSTRACT
| FULL TEXT
Gray Matter in First-Episode Schizophrenia Before and After Antipsychotic Drug Treatment. Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting
Leung et al.
Schizophr Bull 2011;37:199-211.
ABSTRACT
| FULL TEXT
Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis
Koning et al.
Schizophr Bull 2010;36:723-731.
ABSTRACT
| FULL TEXT
Clinical significance of neurological abnormalities in psychosis
Picchioni and Dazzan
Adv. Psychiatr. Treat. 2009;15:419-427.
ABSTRACT
| FULL TEXT
Neurobiology of early psychosis
KESHAVAN et al.
Br. J. Psychiatry 2005;187:s8-s18.
ABSTRACT
| FULL TEXT
Thara et al.
Br. J. Psychiatry 2004;184:366-373.
FULL TEXT
Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia
McCREADIE et al.
Br. J. Psychiatry 2003;183:45-49.
ABSTRACT
| FULL TEXT
Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up
McCREADIE et al.
Br. J. Psychiatry 2002;181:135-137.
ABSTRACT
| FULL TEXT
|